Boots was drawn into a major credibility controversy in 2009 when superintendent pharmacist Paul Bennett appeared before the House of Commons Science and Technology Committee to discuss the company’s sale of homeopathic medicines. Bennett acknowledged that Boots had no evidence demonstrating that the remedies were efficacious, yet continued to sell them on the grounds of “consumer choice.” The admission was especially damaging because Boots traded on the authority and trust associated with professional pharmacy while placing scientifically unsupported products beside conventional medicines. The comments generated widespread media criticism, and in 2010 protesters staged a mass homeopathy “overdose” outside Boots stores to dramatize the claim that the products were no more effective than placebos. The episode became part of Britain’s larger argument over whether pharmacies should sell treatments that lack credible evidence, and whether consumer demand alone was an adequate justification for doing so.
Preparing the daily feature…
AI concept artworkArchive Record · 2000s
Boots Admitted It Sold Homeopathic Remedies Without Evidence
Boots UK / 2000s
Boots was drawn into a major credibility controversy in 2009 when superintendent pharmacist Paul Bennett appeared before the House of Commons Science and Technology Committee to discuss the company’s sale of homeopathic medicines. Bennett acknowledged that Boots had no evidence demonstrating that the remedies were efficacious, yet continued to sell them on the grounds of “consumer choice.” The admission was especially damaging because Boots traded on the authority and trust associated with professional pharmacy while placing scientifically unsupported products beside conventional medicines. The comments generated widespread media criticism, and in 2010 protesters staged a mass homeopathy “overdose” outside Boots stores to dramatize the claim that the products were no more effective than placebos. The episode became part of Britain’s larger argument over whether pharmacies should sell treatments that lack credible evidence, and whether consumer demand alone was an adequate justification for doing so.
The daily editorial is currently unavailable. There’s still an entire archive to explore.